---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055063"
form_type: "8-K"
ticker: null
cik: "0001840574"
company_name: "Verve Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T13:03:43.728976+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verve Therapeutics reports Q1 2024 net loss of $48.7M; cash runway to late 2026; VERVE-102 first patient dosed

## Summary
- Net loss of $48.7M ($0.59 per share) vs $52.0M in Q1 2023; R&D expenses $48.4M.
- Cash, cash equivalents, and marketable securities $606.4M; cash runway into late 2026.
- First patient dosed in Heart-2 Phase 1b trial of VERVE-102 (PCSK9); data update expected 2025.
- VERVE-201 (ANGPTL3) Phase 1b initiation on track for H2 2024; completed preclinical studies.
- Received first milestone payment from Eli Lilly for Lp(a) collaboration; total potential milestones up to $465M.

## SEC filing metadata
- accession: 0000950170-24-055063
- form_type: 8-K
- cik: 0001840574
- company_name: Verve Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840574/000095017024055063/0000950170-24-055063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840574/000095017024055063/verv-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055063
- JSON: https://secwatch.observer/filing/0000950170-24-055063.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055063.txt

## Key facts
- Earnings Releases
  Verve Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, Verve Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840574/000095017024055063/0000950170-24-055063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.